Amphotericin B Hepatotoxicity: Recognition and Management
Hepatotoxicity with amphotericin B is uncommon but documented, manifesting primarily as asymptomatic elevations in liver enzymes (alkaline phosphatase, AST, ALT, bilirubin) that typically resolve upon drug discontinuation. 1
Clinical Presentation and Monitoring
Signs of Hepatotoxicity
The FDA label explicitly recommends monitoring liver function regularly during amphotericin B therapy 1. Hepatotoxicity typically presents as:
- Asymptomatic elevation of liver enzymes (most common presentation) 2
- Increased alkaline phosphatase, AST, ALT, LDH, and bilirubin 2
- Rarely progresses to clinically significant liver dysfunction 3
The incidence of hepatotoxicity ranges from 18-23% in reported series, though severe acute or subacute hepatotoxicity is very rare 4, 3. Importantly, hepatotoxicity is reversible in the vast majority of cases when the drug is discontinued 5, 2.
Monitoring Protocol
Based on FDA guidance and clinical evidence 1:
- Baseline liver function tests before initiating therapy
- Regular monitoring of liver enzymes during treatment (specific intervals at 1,2, and 4 weeks, then every 3 months have been recommended for azoles 6; similar vigilance is prudent for amphotericin B)
- Monitor hepatic function alongside renal function, serum electrolytes (magnesium and potassium), blood counts, and hemoglobin 1
Risk Factors and Clinical Context
High-Risk Scenarios
Exercise particular caution in patients with:
- Pre-existing hepatic injury or dysfunction 4
- Concomitant use of other hepatotoxic agents, including azole antifungals (itraconazole, fluconazole) 5
- Critically ill patients where distinguishing drug-induced hepatotoxicity from illness-related liver abnormalities may be challenging 3
- Immunocompromised patients receiving chemotherapy (though most reports are in this population, immunocompetent patients can also develop hepatotoxicity) 4
Important Consideration
The evidence suggests amphotericin B may interfere with hepatic cytochrome P450, potentially affecting the liver's metabolic capacity 3. This raises concern for drug interactions during prolonged treatment, particularly with medications undergoing hepatic metabolism.
Management Approach
When Hepatotoxicity Develops
Discontinue amphotericin B immediately if significant hepatotoxicity occurs 5, 2. The evidence consistently demonstrates:
- Rapid resolution of liver enzyme elevations upon drug discontinuation 5, 2
- Rechallenge at lower doses may still trigger recurrent hepatotoxicity 2
- Alternative antifungal therapy should be considered rather than rechallenge
Alternative Formulations
Liposomal amphotericin B (L-AMB) may be considered as an alternative, though hepatotoxicity has been reported with lipid formulations as well 7, 8. In one study, 21% of patients receiving L-AMB developed hepatotoxicity, though no specific correlates (age, dose escalation, cumulative dose) were significantly associated with its occurrence 7.
Practical Algorithm
- Detect elevation: Monitor liver enzymes regularly during therapy
- Assess severity: Determine if elevation is mild (continue with close monitoring) or significant (>3x upper limit of normal for transaminases or bilirubin >1.5 mg/dL)
- Evaluate causality: Rule out other causes (underlying disease, other medications, sepsis)
- If significant hepatotoxicity confirmed:
- Discontinue amphotericin B immediately
- Switch to alternative antifungal (azole or echinocandin based on organism susceptibility)
- Monitor liver enzymes for resolution
- Do not rechallenge with amphotericin B if severe hepatotoxicity occurred
Critical Pitfalls
- Do not assume liver abnormalities are solely due to underlying illness in critically ill patients; amphotericin B can contribute 3
- Avoid combining amphotericin B with other hepatotoxic agents when possible, particularly azole antifungals 5
- Do not overlook the need for baseline liver function assessment before starting therapy 1
- Remember that lipid formulations are not completely free of hepatotoxicity risk, though they have improved safety profiles overall 7